New ‘ground-breaking’ bowel cancer vaccine to go on trial at hospital
The treatment will trialled at the Royal Surrey NHS Foundation Trust and Queen Elizabeth Hospital in Adelaide.
Your support helps us to tell the story
This election is still a dead heat, according to most polls. In a fight with such wafer-thin margins, we need reporters on the ground talking to the people Trump and Harris are courting. Your support allows us to keep sending journalists to the story.
The Independent is trusted by 27 million Americans from across the entire political spectrum every month. Unlike many other quality news outlets, we choose not to lock you out of our reporting and analysis with paywalls. But quality journalism must still be paid for.
Help us keep bring these critical stories to light. Your support makes all the difference.
Health experts have hailed a potentially “ground-breaking” vaccine to treat early bowel cancer set to go on trial in England and Australia.
The treatment will trialled at the Royal Surrey NHS Foundation Trust and Queen Elizabeth Hospital in Adelaide.
Doctors plan to administer the vaccine to patients before surgery, in the hope that it will cause the body to attack the cancer.
It would make any surgery less invasive and medics hope that the strength of the vaccine could support the immune system to respond if there is a relapse and the cancer returns later on.
Dr Tony Dhillon, chief investigator of the trial and Surrey’s consultant medical oncologist, proposed the idea for the trial and has worked with Professor Tim Price in Australia for the last four years to develop the vaccine.
He said: “This is the first treatment vaccine in any gastrointestinal cancer and we have high hopes that it will be very successful. We think that for a lot of patients, the cancer will have gone completely after this treatment.”
The trial will be run by the Cancer Research UK Southampton Clinical Trials Unit at the University of Southampton in collaboration with Surrey and the Queen Elizabeth Hospital.
There will be 10 sites for patients to be enrolled – six in Australia and four in the UK, with 44 patients to be enrolled in the study over an 18 month period.
Patients will have an endoscopy, then a tissue sample will be tested to see if they are eligible for the trial. If they are, they will have three doses of the vaccine before having surgery to remove the cancer.
The trial will be available for just 44 patients around the world. After the trial finishes, the vaccine will either be licensed for use, or if it’s successful, a bigger study will be carried out.
The vaccine has been designed by Imugene Ltd, a clinical stage immuno-oncology company.
Dr Dhillon added: “This is ground-breaking. I feel as if we are on the edge of something really big here. The vaccine makes the immune system go after the cancer.
“It will be life changing because it means that potentially, patients may not need to have surgery – they may just have the vaccine.
“The work we have done here at Royal Surrey is fantastic. We are hugely proud to have been involved in this worldwide trial and believe it could be key to treating bowel cancer in the future.”
Louise Stead, Surrey’s chief executive, said: “We are hugely proud to have been involved in the launch of this ground-breaking new vaccine.
“As the fourth largest cancer centre in the UK, helping to fight cancer is a huge part of what we do and this will really provide an opportunity for bowel cancer patients and give them real hope of beating the disease.
“I would like to say a huge well done to Dr Tony Dhillon and everyone associated with this trial for all their hard work.”
Bowel cancer, also known as colorectal cancer, is the third most common cancer, with a worldwide annual incidence of over 1.2 million cases and a mortality rate of approximately 50 per cent.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments